Seeking Alpha
Editor's notes: Under-followed ELOS has growing sales and multiple new products in the pipeline. Recent competitor valuations should bring new attention to the stock and its 60% upside.

Two recent events prove that Syneron-Candela (TICKER: ELOS), the leader in aesthetic medical devices, is trading at a deep discount to its universe. In fact, Syneron should trade not at its peer multiples but at a premium, for reasons detailed below. We initiate coverage on Syneron with a Strong Buy recommendation supported by 2 major transactions, and set a target price of $18. Syneron closed last night at $11.30 per share.

The first event occurred on December 6, 2013, when Lumenis filed for a $115 million IPO on NASDAQ. Lumenis is one of the main competitors of Syneron. The prospectus and the planned IPO clearly show how Syneron, the larger of the 2 companies, is trading at a...

Only subscribers can access this article, which is part of the PRO research library covering 3,796 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: